Indoco Remedies received a warning letter from the USFDA for its Goa manufacturing plant after failing to meet compliance standards. The company is working to resolve the issues. Dec 17, 2024 16:33 ...

Indoco Remedies Limited had earlier received Official Action ... 33 - 34 Verna Industrial Estate Area, Verna, Goa, India ("Facility"). Subsequently, the Facility has received a warning letter ...

Shares of Indoco Remedies Ltd. fell as much as 6% on Tuesday, December 17, after the company's facility in Verna, Goa, received a warning letter from the United States Food & Drug Administration ...

This is further to our notification dated October 11, 2024, for receipt of Official Action Indicated (OAI) status from the USFDA for Plant II & Plant III facility located at Goa (Facility).

Wardwizard Innovations & Mobility Limited (WIML ... 33 - 34 Verna Industrial Estate Area, Verna, Goa, India. Indoco Remedies stock plummeted 7.22% on the NSE, trading at ₹315.95.

The Indian Pharmaceuticals industry plays a prominent role in the growth of the global pharmaceuticals industry. Indias pharmaceutical market, currently valued at $ 50 billion is the worlds third ...

In a setback for Indoco Remedies, the pharma company informed that it has received a warning letter from the USFDA for its facility in Goa's Verna region on December 17, sending the shares sharply ...

Shares of Indoco Remedies rose 1.85 per cent to ₹346.90 ... for its plant II and III facility located in Verna, Goa, India. According to its exchange filing, the USFDA inspection has conducted ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Indoco Remedies has surged over 17% in the past month, breaking above the neckline of an inverse head & shoulder pattern. Experts suggest the stock could reach Rs 430 levels in the next 1-2 months.

March 9 (Reuters) - Indoco Remedies Ltd INRM.NS : * INDOCO REMEDIES LTD - ANNOUNCES LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION 1% IN THE US MARKET BY TEVA PHARMACEUTICALS Feb 9 (Reuters) - Indoco ...